MCID: MTS005
MIFTS: 11

Metastatic Squamous Neck Cancer with Occult Primary

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Metastatic Squamous Neck Cancer with Occult Primary

MalaCards integrated aliases for Metastatic Squamous Neck Cancer with Occult Primary:

Name: Metastatic Squamous Neck Cancer with Occult Primary 52

Classifications:



Summaries for Metastatic Squamous Neck Cancer with Occult Primary

MalaCards based summary : Metastatic Squamous Neck Cancer with Occult Primary The drugs Sargramostim and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and lung.

Related Diseases for Metastatic Squamous Neck Cancer with Occult Primary

Symptoms & Phenotypes for Metastatic Squamous Neck Cancer with Occult Primary

Drugs & Therapeutics for Metastatic Squamous Neck Cancer with Occult Primary

Drugs for Metastatic Squamous Neck Cancer with Occult Primary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
2
Promethazine Approved, Investigational Phase 3 60-87-7 4927
3
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
4
Histamine Approved, Investigational Phase 3 51-45-6 774
5
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
6
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
7
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
8
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
9
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
10
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
11
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
14
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Fluorouracil Approved Phase 3 51-21-8 3385
17 Molgramostim Investigational Phase 3 99283-10-0
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Neurotransmitter Agents Phase 3
20 Analgesics Phase 3
21 Mitogens Phase 3
22 Anti-Infective Agents Phase 2, Phase 3
23 Cola Phase 3
24 Antidepressive Agents Phase 3
25 Hypnotics and Sedatives Phase 3
26 Histamine Antagonists Phase 3
27 Psychotropic Drugs Phase 3
28
Histamine Phosphate Phase 3 51-74-1 65513
29 Antidepressive Agents, Tricyclic Phase 3
30 Muscarinic Agonists Phase 3
31 Cholinergic Agents Phase 3
32 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
33 Hormone Antagonists Phase 2, Phase 3
34 Antifungal Agents Phase 2, Phase 3
35 Liver Extracts Phase 3
36 Central Nervous System Stimulants Phase 3
37 Contraceptives, Oral Phase 3
38 Antineoplastic Agents, Hormonal Phase 3
39 Contraceptive Agents Phase 3
40
Megestrol Phase 3 3562-63-8 19090 3080587
41 Anesthetics Phase 3
42 Narcotics Phase 3
43 Analgesics, Opioid Phase 3
44 Anesthetics, General Phase 3
45 Anesthetics, Intravenous Phase 3
46 Immunologic Factors Phase 3
47 Immunosuppressive Agents Phase 3
48 Antimetabolites Phase 3
49 Albumin-Bound Paclitaxel Phase 3
50
Temoporfin Approved, Investigational Phase 2 122341-38-2

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
2 Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00003809 Phase 3 cisplatin
3 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
4 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
7 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
8 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
9 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Versus Chemotherapy Alone Terminated NCT00113399 Phase 3 cisplatin;docetaxel;fluorouracil;paclitaxel
12 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
13 Phase I/II Study of High Dose Limited Volume Postoperative Reirradiation in Recurrent or Second Primary Carcinoma of the Head and Neck Unknown status NCT00004226 Phase 1, Phase 2
14 A Phase II, Multicenter, Open Label Study to Evaluate Effectiveness and Safety of AdCMV-p53 Administered by Intra-Tumoral Injections in 39 Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Unknown status NCT00003257 Phase 2
15 A Multicenter, Multi-National, Open-Label, Single Group, Single and Multiple Dose Study of Foscan-Mediated Photodynamic Therapy (PDT) for the Palliative Treatment of Recurrent, Refractory or Second Primary Squamous Cell Carcinomas of the Head and Neck in Patients Considered to be Incurable With Surgery or Radiotherapy Unknown status NCT00003856 Phase 2 temoporfin
16 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
17 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
18 Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed NCT00337129 Phase 2 eribulin mesylate
19 A Phase II Study of Fenretinide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00006471 Phase 2 Fenretinide
20 A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00020189 Phase 2 acetylsalicylic acid;alvocidib;clopidogrel bisulfate
21 A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
22 A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00004070 Phase 1, Phase 2
23 Evaluation of the Combination of Docetaxel (Taxotere)/ Carboplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00003908 Phase 2 carboplatin;docetaxel
24 A Phase II Study of Thalidomide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00003850 Phase 2 thalidomide
25 A Phase II Study of ZD 1839 (Iressa) in Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Completed NCT00024089 Phase 2 gefitinib
26 A Phase II Stdy of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00015964 Phase 2 ZD1839
27 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
28 Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
29 Phase 2 Study Assessing the Impact of Parenteral Administration of the Immunomodulater Oral IMPACT® for Postoperative Radiochemotherapy in Patients With Carcinoma of the Head and Neck Completed NCT00559156 Phase 2 cisplatin
30 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
31 Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00095927 Phase 2 Amifostine;Carboplatin;Paclitaxel
32 Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck Carcinoma Completed NCT00040807 Phase 2 docetaxel;irinotecan hydrochloride
33 Phase II Study Of NX 211 (Liposomal Lurtotecan) Given As An IV Bolus Injection On Days 1 and 8 Every 3 Weeks In Patients With Metastatic Or Loco-Regional Recurrent Squamous Cell Carcinoma Of The Head and Neck With Target Lesions Within Previously Irradiated Fields Or Outside Previously Irradiated Fields Completed NCT00022594 Phase 2 liposomal lurtotecan
34 Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck Completed NCT00003264 Phase 2 cisplatin;gemcitabine hydrochloride
35 Phase II Study of Gemcitabine and Docetaxel (GEMDOC) Combination in Patients With Previously Treated Recurrent or Metatstatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00248560 Phase 2 docetaxel;Gemcitabine
36 Genotypic-Based Pharmacodynamic Evaluation of Erlotinib (Erlotinib (Tarceva™, OSI Pharmaceuticals, Uniondale, NY) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00281866 Phase 2 erlotinib hydrochloride
37 Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma Completed NCT00387335 Phase 2 sunitinib malate
38 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
39 A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Completed NCT00098631 Phase 2 lapatinib ditosylate
40 Phase II Study of Paclitaxel and Cisplatin in Combination With Split Course Concomitant Hyperfractionated Re-Irradiation in Patients With Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00005087 Phase 2 cisplatin;paclitaxel
41 Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Combination With Chemotherapy in Patients With Metastatic or Recurrent Squamous Cell Head and Neck Carcinoma Completed NCT00004865 Phase 2 cisplatin;fluorouracil;paclitaxel
42 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
43 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
44 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
45 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
46 A Phase II Study of Oxaliplatin in Patients With Advanced Carcinoma of the Head and Neck Completed NCT00005035 Phase 2 oxaliplatin
47 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
48 A Phase II Study Of Submandibular Salivary Gland Transfer To The Submental Space Prior To Start Of Radiation Treatment For Prevention Of Radiation-Induced Xerostomia In Head And Neck Cancer Patients Completed NCT00068237 Phase 2
49 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
50 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib

Search NIH Clinical Center for Metastatic Squamous Neck Cancer with Occult Primary

Genetic Tests for Metastatic Squamous Neck Cancer with Occult Primary

Anatomical Context for Metastatic Squamous Neck Cancer with Occult Primary

MalaCards organs/tissues related to Metastatic Squamous Neck Cancer with Occult Primary:

40
Brain, Liver, Lung, Prostate, Endothelial, Lymph Node, Salivary Gland

Publications for Metastatic Squamous Neck Cancer with Occult Primary

Variations for Metastatic Squamous Neck Cancer with Occult Primary

Expression for Metastatic Squamous Neck Cancer with Occult Primary

Search GEO for disease gene expression data for Metastatic Squamous Neck Cancer with Occult Primary.

Pathways for Metastatic Squamous Neck Cancer with Occult Primary

GO Terms for Metastatic Squamous Neck Cancer with Occult Primary

Sources for Metastatic Squamous Neck Cancer with Occult Primary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....